TABLE 1.
Toxicity and relative potencies of the active Cry proteins to neonate Lobesia botrana larvaea
| Cry protein | Regression value ± SE
|
LC50 (μg/ml) | Goodness of fit value
|
Relative potency | 95% CI
|
|||
|---|---|---|---|---|---|---|---|---|
| Slope | ab | χ2 | df | Lower | Upper | |||
| Cry1Ab | 1.9 ± 0.2 | 4.7 ± 0.1 | 1.4 | 0.3 | 3 | 1 | ||
| Cry1Ia | 2.9 ± 0.2 | 2.3 ± 0.2 | 8.5 | 0.7 | 3 | 0.2 | 0.1 | 0.3 |
| Cry2Aa | 2.6 ± 0.3 | 3.7 ± 0.3 | 3.2 | 1.8 | 3 | 0.4 | 0.3 | 0.6 |
| Cry2Ab | 1.7 ± 0.2 | 6.3 ± 0.2 | 0.1 | 1.3 | 3 | 9.0 | 6.3 | 12.9 |
| Cry9Ca | 2.6 ± 0.3 | 7.7 ± 0.3 | 0.09 | 0.1 | 3 | 16.1 | 11.6 | 22.3 |
| HD-1c | 1.9 ± 0.2 | 5.7 ± 0.1 | 0.44 | 0.9 | 3 | 3.3 | 2.3 | 4.7 |
a
Parameters were obtained from the POLO-PC program (24). The χ2 value was not significant (P > 0.05) by a goodness of fit test for each regression. Slopes could not be fitted in parallel. The relative potencies were calculated with respect to that for Cry1Ab, and the values were expressed as the ratio of the LC50 value for each Cry protein to the LC50 value for Cry1Ab (31).
b
a, intercept of the regression line.
c
HD-1 means the entire content of the Cry proteins obtained from the B. thuringiensis kurstaki HD-1 strain.